

Excelra, HotSpot Therapeutics partner for treatment of cancer, autoimmune disease

26 May 2022 | News

HotSpot Therapeutics plans to deploy data from Excelra's flagship product GOSTAR toward select protein targets



Hyderabad-based firm Excelra, a leading global data and digital insights organisation, has announced a partnership with HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases.

HotSpot Therapeutics plans to deploy data from Excelra's flagship product GOSTAR toward select protein targets to augment its allosteric inhibitor candidate pipeline.

The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models.

With the integration of GOSTAR data, HotSpot will continue to advance the discovery and development of small molecule therapy candidates directed toward allosteric targets that have been difficult to drug or undruggable with traditional small molecule approaches.